Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.64 | $0 | -$3M |
| 2025 Q4 | -1.15 | $0 | -$4M |
| 2025 Q3 | -5.00 | $0 | -$3M |
| 2025 Q2 | -8.50 | $0 | -$4M |
| 2025 Q1 | -13.00 | $0 | -$4M |
| 2024 Q4 | -21.00 | $0 | -$4M |
| 2024 Q3 |
| -61.50 |
| $0 |
| -$1M |
| 2024 Q2 | -150.00 | $0 | -$6M |